Sixfold Bioscience, an RNA delivery company, today announced their upcoming presentation at the ELRIG Therapeutic Oligo and European Chemical Biology Symposium in AZ Gothenburg.
The event will see speakers from Roche, AstraZeneca, Ionis, Silence Therapeutics, Oxford University, Inserm, UCSD, Sixfold (and others) converge at the Astra Zeneca site in Gothenburg for three days, from Tuesday 9th to Thursday 11th of May, 2023.
Sixfold Bioscience team lead of Structure & Characterization, Dr. Alice Ghidini, will be presenting her talk on “‘Harnessing RNA-protein binding for nucleic acids therapeutics design improvement” at 11:10 am CET on Tuesday 9th.
This years’ themes are:
Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company, founded in 2017, based at the Translation & Innovation Hub in White City, London. Sixfold develops programmable drug delivery systems, with a current focus on siRNA and ASO.
Sixfold’s RNA delivery platform, Mergo®, was conceived by co-founders Dr Perdrix Rosell and Dr George Foot, who were left frustrated by current delivery systems that were either too toxic or faced complex engineering challenges. The Company’s differentiated approach is based on engineering biocompatible nano-architectures with precise chemical profiles that guide the RNA to selected organs.
UK pumps £13M into wide-ranging group of manufacturing projects
August 22, 2023Read more
Sixfold Bioscience Announces Formation of Scientific Advisory Board
August 9, 2023Read more
Sixfold Bioscience joins UK biotech leaders in Parliament
July 5, 2023Read more
A revolution in targeted RNA delivery [Nature Biopharma]
June 1, 2023Read more